SEC Form 4 · accession 0001104659-26-080806
Liminatus Pharma, Inc. · LIMN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Chris Kim
Officer — Chief Executive Officer · Director · 10% Owner
Valetudo Therapeutics LLC
10% Owner
Period of report
Jun 24, 2026
Accepted (ET)
Jul 6, 2026 · 4:59 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001971387
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.0001 per shareF2,F1 | Jun 24, 2026 | J | 4,373,603 | — | D | 1,795,803 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Consists of 1,795,803 shares of common stock held of record by Valetudo Therapeutics LLC ("Valetudo"). On June 24, 2026, Valetudo transferred 4,373,603 shares of common stock to Ewon Comfortech Co., Ltd and retains voting power over such shares pursuant to a voting agreement. Mr. Chris Kim is the CEO and controlling member of Valetudo and has voting and dispositive power over, and may be deemed to be the beneficial owner of, the shares held by Valetudo. The business address of Valetudo is 2251 Stern Goodman Street, Suite E, Fullerton, California 92833. Mr. Kim disclaims any beneficial ownership of any shares held by Valetudo except to the extent of his ultimate pecuniary interest therein.
- F2The reported transaction involves a transfer of securities for which no payment of consideration was received.